SOUTH SAN FRANCISCO, Calif., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB) today announced that the Company has entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI) for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer.
